In the Margins

Valeant names hedge fund partner to board

October 26, 2015

By Forbes

Valeant Pharmaceuticals has named Mason Morfit, a partner at activist hedge fund ValueAct Capital, to its board of directors. Morfit previously served on the embattled specialty drugmaker's board from 2007 to 2014; ValueAct is one of Valeant's largest shareholders. Read the original story from Forbes

 

 

Most Read

Top of the Agenda - Compensation
IDC study: Director pay up more than 5% in 2022

Independent mutual fund directors earned more in 2022 than they did in 2021, according to industry data obtained by Fund Board Views. The year-on-year increase—a median of ...